Celgene Corporation

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • Bioinformatics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals

Other Names/Subsidiaries

  • Abraxis BioScience, Inc.
  • AbVitro, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Avila Therapeutics, Inc.
  • Delinia, Inc.
  • EngMab AG
  • Gloucester Pharmaceuticals, Inc.
  • Impact Biomedicines, Inc.
  • Juno Therapeutics, Inc.
  • Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
  • JW Biotechnology (Shanghai) Co., Ltd
  • Pharmion Corporation
  • Quanticel Pharmaceuticals, Inc.
  • Receptos, Inc.
  • RedoxTherapies, Inc.
  • X-BODY, Inc.
See more in Biomedtracker

Latest on Celgene Corporation

In Vivo

Big Biotech’s ROI Overshadowed By Big Pharma But Exceptions Exist

 
• By Edwin Elmhirst

In April 2024 Citeline’s Scrip publication reviewed the internal and external R&D inputs of the top 15 companies by sales of prescription and over-the-counter drugs in 2023. This analysis reve

Scrip

Stock Watch: Smiles And Survivorship In BMS’s Q2 Earnings

 
• By Andy Smith

Few Clouds At BMS It must have been all smiles at Bristol Myers Squibb Company (BMS) when its second-quarter earnings announcement propelled its stock price up by over 11%, more than double the st

Pink Sheet

BIO Notebook: US FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More

 
• By Pink Sheet Team

AI And FDA: A Risk-Based Approach And New Industry User Fees? The US Food and Drug Administration likely will need a risk-based approach to reviewing the artificial intelligence aspects of drug applic

Scrip

BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More

 
• By Scrip Team

The Pros And Cons Of Flying Solo With Ex-US Launches There is plenty of money to be made in the international markets for US biotechs, but deciding to go it alone or find a partner abroad remains a tr